Merrimack Pharmaceuticals Inc (MACK)

Form 15-12G - Securities registration termination [Section 12(g)]

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

Form 8-K - Current report

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a...

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (Nasdaq:...

Merrimack Receives $225 Million Milestone Payment from Ipsen

Special Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time Merrimack...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Merrimack Reports Full Year 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form PRE 14A - Other preliminary proxy statements